Clinical Trials Logo

Pancreatic Neoplasms clinical trials

View clinical trials related to Pancreatic Neoplasms.

Filter by:

NCT ID: NCT06378853 Completed - Pancreatic Cancer Clinical Trials

Risk Factors of Postoperative Complications and Survival Rate in Pancreatic Ductal Adenocarcinoma Patients

Start date: January 1, 2019
Phase:
Study type: Observational

By evaluating the nutritional status of patients with pancreatic ductal adenocarcinoma (PDAC) admitted to Jinling Hospital, collecting relevant clinical data. we aim to conduct correlation analysis with patient clinical information, such as survival time, hospitalization time, nutritional status, hematological indicators, etc., in order to reveal the prognostic factors for overall survival and postoperative complications of PDAC patients.

NCT ID: NCT06378047 Recruiting - Pancreatic Cancer Clinical Trials

Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

Start date: April 10, 2024
Phase: Phase 1
Study type: Interventional

This study aims to determine the safety and tolerability of combining sequential therapy of Irreversible Electroporation (IRE) and Immunotherapy (IO) for patients with locally advanced unresectable pancreas cancer following first-line treatment with chemotherapy and ablative stereotactic magnetic resonance image-guided adaptive radiation therapy (A-SMART).

NCT ID: NCT06375473 Not yet recruiting - Pancreatic Cancer Clinical Trials

Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients

MA-PC-RWS-011
Start date: April 19, 2024
Phase:
Study type: Observational

This study is a multi-center observational study.The start time for data collection is May 1, 2024. Patients' baseline and treatment data will be collected under informed concent. The purpose of this case registry study was to evaluate the safety and efficacy of irinotecan hydrochloride liposome injection II based therapy in Chinese patients with pancreatic cancer in the real world by collecting, understanding, and analyzing the etiology, clinical features, treatment pattern, treatment outcomes, and pharmacoeconomics changes in pancreatic cancer patients receiving this regimen.

NCT ID: NCT06370754 Not yet recruiting - Pancreatic Cancer Clinical Trials

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

FD-IMPACT
Start date: April 30, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase Ib/II platform clinical study to evaluate the initial efficacy and safety of different novel immunotherapies in patients with advanced pancreatic cancer.

NCT ID: NCT06368063 Not yet recruiting - Clinical trials for Pancreatic Cancer Resectable

The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer

Start date: April 2024
Phase: Phase 4
Study type: Interventional

The study is a multicenter, prospective clinical study aimed at evaluating the efficacy and safety of Huaier Granule in postoperative adjuvant treatment of resectable pancreatic cancer

NCT ID: NCT06363084 Completed - Clinical trials for Resectable Pancreatic Cancer

A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Start date: May 1, 2016
Phase:
Study type: Observational

This trial is a retrospective, observational study, patients who underwent surgical resection of the pancreas for non-metastatic pancreatic cancer between 2016 and 2022 were selected and divided into two groups according to with (study arm) or without (control arm) nimotuzumab. The primary efficacy endpoint was overall survival (OS).

NCT ID: NCT06361888 Not yet recruiting - Clinical trials for Metastatic Pancreatic Cancer

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Start date: May 31, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

To evaluate the efficacy of Surufatnib combined withcamrelizumab, nab-paclitaxel, and gemcitabine versus nab-paclitaxel plus gemcitabine as the first-line treatment in metastatic pancreatic cancer

NCT ID: NCT06361316 Recruiting - Pancreatic Cancer Clinical Trials

Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer

Start date: April 8, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of irinotecan liposome injection in combined with oxaliplatin plus tegafur (NASOX) for postoperative adjuvant chemotherapy for pancreatic cancer.

NCT ID: NCT06361030 Not yet recruiting - Pancreatic Cancer Clinical Trials

Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer

Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of surufatinib combined with gemcitabine plus nab-paclitaxel in patients with locally advance d pancreatic cancer

NCT ID: NCT06360354 Recruiting - Clinical trials for Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion

Start date: May 1, 2024
Phase: Phase 1
Study type: Interventional

The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted gastrointestinal, biliary tract, or pancreatic cancers.